Patents by Inventor James G. Respess
James G. Respess has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7070994Abstract: The invention described herein allows the production of recombinant retroviruses (retroviral vector particles) from producer cells which are safer and of higher titer than normal. In addition, methods are provided for making helper cells which, when a recombinant retrovirus genome is introduced to make a producer line, produce particles that are targeted toward particular cell types. Methods are also provided for making recombinant retrovirus systems adapted to infect a particular cell type, such as a tumor, by binding the retrovirus or recombinant retrovirus in the particular cell type. Methods are also provided for producing recombinant retroviruses which integrate in a specific small number of places in the host genome, and for producing recombinant retroviruses from transgenic animals.Type: GrantFiled: July 24, 2002Date of Patent: July 4, 2006Assignee: Oxford Biomedica (UK) Ltd.Inventors: Jack R. Barber, Douglas J. Jolly, James G. Respess, Stephen M. W. Chang
-
Patent number: 6818439Abstract: Methods are provided for obtaining measurable levels of a protein, nucleic acid molecule, or enzymatic product in a bodily fluid or cells of a human, comprising the step of administering to a human a recombinant retroviral preparation having a titer on HT1080 cells of greater than 105 cfu/ml, wherein the recombinant retroviral preparation is capable of directing the expression of a protein, nucleic acid molecule, or enzyme which generates an enzymatic product, such that measurable levels of the protein, nucleic acid molecule, or enzymatic product may be obtained in the bodily fluid or cells of the human.Type: GrantFiled: December 30, 1997Date of Patent: November 16, 2004Assignee: Chiron CorporationInventors: Douglas J. Jolly, Stephen Chang, James G. Respess, Nicholas J. DePolo, David Chi-Tang Hsu, Carlos E. Ibanez, Judith Greengard, Lee Will
-
Publication number: 20030051259Abstract: The invention described herein allows the production of recombinant retroviruses (retroviral vector particles) from producer cells which are safer and of higher titre than normal. In addition, methods are provided for making helper cells which, when a recombinant retrovirus genome is introduced to make a producer line, produce particles that are targeted toward particular cell types. Methods are also provided for making recombinant retrovirus systems adapted to infect a particular cell type, such as a tumor, by binding the retrovirus or recombinant retrovirus in the particular cell type. Methods are also provided for producing recombinant retroviruses which integrate in a specific small number of places in the host genome, and for producing recombinant retroviruses from transgenic animals.Type: ApplicationFiled: July 8, 2002Publication date: March 13, 2003Inventors: Jack R. Barber, Douglas J. Jolly, James G. Respess, Stephen M.W. Chang
-
Publication number: 20030003567Abstract: The invention described herein allows the production of recombinant retroviruses (retroviral vector particles) from producer cells which are safer and of higher titer than normal. In addition, methods are provided for making helper cells which, when a recombinant retrovirus genome is introduced to make a producer line, produce particles that are targeted toward particular cell types. Methods are also provided for making recombinant retrovirus systems adapted to infect a particular cell type, such as a tumor, by binding the retrovirus or recombinant retrovirus in the particular cell type. Methods are also provided for producing recombinant retroviruses which integrate in a specific small number of places in the host genome, and for producing recombinant retroviruses from transgenic animals.Type: ApplicationFiled: July 24, 2002Publication date: January 2, 2003Inventors: Jack R. Barber, Douglas J. Jolly, James G. Respess, Stephen M.W. Chang
-
Patent number: 6495349Abstract: Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.Type: GrantFiled: June 5, 1995Date of Patent: December 17, 2002Inventors: Harry E. Gruber, Douglas J. Jolly, James G. Respess, Paul K. Laikind
-
Patent number: 6410326Abstract: Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.Type: GrantFiled: June 7, 1995Date of Patent: June 25, 2002Assignee: Chiron CorporationInventors: Harry E. Gruber, Douglas J. Jolly, James G. Respess, Paul K. Laikind, Jack R. Barber, Daniel C. St. Louis, Sunil D. Chada, Stephen M. W. Chang, John F. Warner
-
Patent number: 6333195Abstract: Retroviral vector constructs are described which have a 5′ LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand synthesis and a 3′ LTR, wherein the vector construct lacks retroviral gag/pol or env coding sequences. In addition, gag/pol, and env expression cassettes are described wherein the expression cassettes lack a consecutive sequence of more than 8 nucleotides in common. The above-described retroviral vector constructs, gag/pol and env expression cassettes may be utilized to construct producer cell lines which preclude the formation of replication competent virus.Type: GrantFiled: January 7, 2000Date of Patent: December 25, 2001Assignee: Chiron CorporationInventors: James G. Respess, Nicholas J. DePolo, Sunil Chada, Sybille Sauter, Mordechai Bodner, David A. Driver
-
Patent number: 6310045Abstract: The present invention provides methods for inhibiting the growth of selected tumors utilizing recombinant viral vectors. Briefly, within one aspect of the present invention, a method for inhibiting the growth of a selected tumor is provided comprising the step of directly administering to a warm-blooded animal a vector construct which directs the expression of at least one anti-tumor agent, such that the growth of said tumor is inhibited. Representative examples of anti-tumor agents include immune activators and tumor proliferation inhibitors.Type: GrantFiled: June 6, 1995Date of Patent: October 30, 2001Assignee: Chiron CorporationInventors: Jack R. Barber, Douglas J. Jolly, James G. Respess
-
Patent number: 6133029Abstract: Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.Type: GrantFiled: June 6, 1995Date of Patent: October 17, 2000Assignee: Chiron CorporationInventors: Harry E. Gruber, Douglas J. Jolly, James G. Respess, Paul K. Laikind
-
Patent number: 6013517Abstract: Retroviral vector constructs are described which have a 5' LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand synthesis and a 3' LTR, wherein the vector construct lacks retroviral gag/pol or env coding sequences. In addition, gag/pol, and env expression-cassettes are described wherein the expression cassettes lack a consecutive sequence of more than 8 nucleotides in common. The above-described retroviral vector constructs, gag/pol and env expression cassettes may be utilized to construct producer cell lines which preclude the formation of replication competent virus.Type: GrantFiled: May 5, 1997Date of Patent: January 11, 2000Assignee: Chiron CorporationInventors: James G. Respess, Nicholas J. DePolo, Sunil Chada, Sybille Sauter, Mordechai Bodner, David A. Driver
-
Patent number: 5888502Abstract: Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.Type: GrantFiled: June 5, 1995Date of Patent: March 30, 1999Inventors: Harry E. Guber, Douglas J. Jolly, James G. Respess, Paul K. Laikind
-
Patent number: 5856185Abstract: Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.Type: GrantFiled: June 7, 1995Date of Patent: January 5, 1999Assignee: Chiron CorporationInventors: Harry E. Gruber, Douglas J. Jolly, James G. Respess, Paul K. Laikind, Jack R. Barber, Daniel C. St. Louis, Sunil D. Chada, Stephen M. W. Chang, John F. Warner
-
Patent number: 5851529Abstract: Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.Type: GrantFiled: June 7, 1995Date of Patent: December 22, 1998Inventors: Harry E. Guber, Douglas J. Jolly, James G. Respess, Paul K. Laikind
-
Patent number: 5830458Abstract: Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.Type: GrantFiled: June 7, 1995Date of Patent: November 3, 1998Inventors: Harry E. Gruber, Douglas J. Jolly, James G. Respess, Paul K. Laikind
-
Patent number: 5716613Abstract: Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.Type: GrantFiled: June 7, 1995Date of Patent: February 10, 1998Assignee: Chiron Viagene, Inc.Inventors: Harry E. Guber, Douglas J. Jolly, James G. Respess, Paul K. Laikind
-
Patent number: 5716826Abstract: Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.Type: GrantFiled: October 12, 1993Date of Patent: February 10, 1998Assignee: Chiron Viagene, Inc.Inventors: Harry E. Gruber, Douglas J. Jolly, James G. Respess, Paul K. Laikind
-
Patent number: 5716832Abstract: The invention described herein allows the production of recombinant retroviruses (retroviral vector particles) from producer cells which are safer and of higher titre than normal. In addition, methods are provided for making helper cells which, when a recombinant retrovirus genome is introduced to make a producer line, produce particles that are targeted toward particular cell types. Methods are also provided for making recombinant retrovirus systems adapted to infect a particular cell type, such as a tumor, by binding the retrovirus or recombinant retrovirus in the particular cell type. Methods are also provided for producing recombinant retroviruses which integrate in a specific small number of places in the host genome, and for producing recombinant retroviruses from transgenic animals.Type: GrantFiled: June 5, 1995Date of Patent: February 10, 1998Assignee: Chiron Viagene, Inc.Inventors: Jack R. Barber, Douglas J. Jolly, James G. Respess, Stephen M. W. Chang
-
Patent number: 5691177Abstract: Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.Type: GrantFiled: June 5, 1995Date of Patent: November 25, 1997Inventors: Harry E. Guber, Douglas J. Jolly, James G. Respess, Paul K. Laikind
-
Patent number: 5681746Abstract: Retroviral vectors for directing expression of full length factor VIII in transduced host cells, plasmids encoding the same, and host cells transformed, transfected, or transduced therewith are disclosed. Also disclosed are retroviral particles comprising such retrovital vectors, as are methods for making such particles in suitable packaging cells. Retroviral particles so produced may be amphotropic, ecotropic, polytropic, or xenotropic; alternatively, they may comprise chimeric or hybrid envelope proteins to alter host range. Also described are retrovital particles comprising retroviral vectors for directing full length factor VIII expression which are complement resistant. Pharmaceutical compositions comprising retrovital particles of the invention are also disclosed, as are methods of treating mammals, particularly humans, afflicted with hemophilia.Type: GrantFiled: December 30, 1994Date of Patent: October 28, 1997Assignee: Chiron Viagene, Inc.Inventors: Mordechai Bodner, Nicholas J. De Polo, Stephen Chang, David Chi-Tang Hsu, James G. Respess
-
Patent number: 5662896Abstract: The present invention provides methods for inhibiting the growth of selected tumors utilizing recombinant viral vectors. Briefly, within one aspect of the present invention, a method for inhibiting the growth of a selected tumor is provided comprising the step of directly administering to a warm-blooded animal a vector construct which directs the expression of at least one anti-tumor agent, such that the growth of said tumor is inhibited. Representative examples of anti-tumor agents include immune activators and tumor proliferation inhibitors.Type: GrantFiled: March 17, 1993Date of Patent: September 2, 1997Assignee: Chiron Viagene, Inc.Inventors: Jack R. Barber, Douglas J. Jolly, James G. Respess